Are you busy during this broadcast? See Broadcast #1 for an alternative time.
AGC Biologics’ proprietary CHEF1® Expression System accelerates development of cell lines for cGMP biologics production. The innovative platform utilizes robust procedures and reliable raw materials, including chemically defined media, adapted Chinese hamster ovary (CHO) cells, and CHEF1 expression plasmids, to produce high levels of recombinant protein in rapid timeframes.
In this webinar our speakers will address:
- A detailed technical review of the platform technology
- An explanation of how pool production enables fast and flexible delivery of early material
- A discussion of how small-scale models ensure seamless and successful manufacturing
- New data regarding CHEF1 performance
Join us to learn more about how CHEF1 significantly accelerates and improves the biologics production process with rapid timelines, competitive titers, a robust platform, regulatory acceptance, and reliable manufacturing productivity.
Christina Rottbøll Andersen, Ph.D., Team Leader, Cell Line Development, AGC Biologics, Copenhagen, Denmark
Christina R. Andersen joined AGC Biologics in April 2015, initially as Scientist in Upstream Process Development and later became Team Leader in Cell Line Development. Dr. Andersen has more than 10 years of experience within cell line development and protein expression in mammalian cells. Prior to joining AGC Biologics, Christina was at Symphogen A/S, mainly focusing on expression of antibodies, generation of antibody expressing cell lines and development of the cell line generation technology platform.
Christina has an Industrial Ph.D. within expression of recombinant proteins in mammalian cells from Copenhagen University, performed at Symphogen, and an M.Sc. in Biotechnology from the Danish Technical University.Message Presenter
Lena Nielsen, Ph.D., Director, Upstream Process Development, AGC Biologics, Copenhagen, Denmark
Lena Nielsen joined AGC Biologics in January 2015 bringing over 15 years’ experience in molecular biology, cell line development and process development. Dr. Nielsen has a proven track record in line management and working in cross-functional and international teams. Prior to joining AGC Biologics, Lena was at BioInvent International, Active Biotech AB and Alligator Bioscience, as Manager/Director of teams mainly focusing on antibody development. She also held a post-doctoral position at Dept of Biochemistry, University of Wisconsin.
Lena has a Ph.D. in Molecular Genetics and an M.Sc. in Biotechnology from Lund University.Message Presenter
Who Should Attend?
Individuals at large and small biopharmaceutical organizations, including:
• Process Development Roles
• Commercial Roles
AGC Biologics is a leading global Contract Development and Manufacturing Organization (CDMO), with a strong commitment to deliver the highest standard of service to our clients and partners. AGC Biologics is the product of the convergence and integration of Asahi Glass Company (AGC) Bioscience, Biomeva GmbH, and CMC Biologics. Our extensive network spans three continents, with cGMP-compliant facilities in Seattle, WA; Berkeley, CA; Copenhagen, Denmark; Heidelberg, Germany; Yokohama, Japan; and Chiba, Japan.
AGC Biologics offers deep industry expertise and uniquely customized services for the scale-up and cGMP manufacture of protein-based therapeutics, from pre-clinical to commercial production, for mammalian and microbial. Our integrated service offerings include cell line development, bioprocess development, formulation, analytical testing, antibody drug development and conjugation, cell banking and storage, and protein expression — including our proprietary CHEF1® Expression System for mammalian production.
Our company DNA drives us to provide innovative solutions for clients to reach their goals and accelerate their projects, as well as facilitate approval and manage spending during the product lifecycle. AGC Biologics forges exceptionally strong partnerships with our clients, and we never lose sight of our commitment to deliver reliable and compliant drug substance supply, on time.